<DOC>
	<DOCNO>NCT01905475</DOCNO>
	<brief_summary>The purpose study investigate effect POL6326 ( CXCR4 antagonist ) stem cell mobilize agent , cardiac function infarct size safety tolerability , patient reperfused ST-Elevation Myocardial Infarction ( STEMI ) .</brief_summary>
	<brief_title>CXCR4 Antagonism Cell Mobilisation Healing Acute Myocardial Infarction ( CATCH-AMI )</brief_title>
	<detailed_description>After acute myocardial infarction successful stent implantation patient undergo baseline MRI ( magnetic resonance imaging ) eligibility study . Patients receive POL6326 placebo first week STEMI . The primary secondary endpoint also determine follow-up visit 12 month . An interim analysis perform 50 % patient complete 4 month MRI assessment may result adjustment study size . A number pre-specified subgroup investigate .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>1 . Patients symptoms suggestive acute MI STsegment elevation new leave bundlebranch block rise fall cardiac necrosis marker . 2 . Patients must schedule undergo coronary angiography purpose primary PCI ( percutaneous coronary intervention ) culminate successful stent implantation . 3 . Age 18 80 year . Male WOCBP ( woman child bear potential ) willing use highly effective method contraception time first dose 3 month last dose drug . 4 . Markedly reduce LVEF baseline cardiac MRI . 5 . No previous occurrence Myocardial Infarction . 6 . Estimated glomerular filtration rate ( eGFR ) equal high 40 mL/minute prior MRI . 7 . Signed Informed Consent . 1 . Evidence multivessel coronary artery disease likely require repeat PCI coronary artery bypass graft within 4 month . 2 . Pulmonary oedema cardiogenic shock require intubation mechanical support time plan baseline MRI . 3 . Fitted nonMRIcompatible cardiac pacemaker implantable cardioverter defibrillator , expect require device within 4 month randomisation . 4 . Terminal illness malignant disease . 5 . Advanced hepatic disease . 6 . Diagnosis severe obesity precludes MRI assessment . 7 . Claustrophobia . 8 . Acute systemic infection fever . 9 . Anemia ( hemoglobin level &lt; 10 g/dL ) , thrombocytopenia ( platelet count &lt; 100000/Î¼L ) coagulopathy . 10 . History multiple drug allergy know allergy drug class CXCR4 antagonists . 11 . Pregnancy female childbearing potential use double contraception 12 . Known history human immunodeficiency virus ( HIV ) infection , chronic hepatitis B hepatitis C infection significant active chronic inflammatory disease require immunosuppressive medication regular systemic corticosteroid . 13 . Patients participate investigational drug device trial within 30 day prior sign inform consent . 14 . Patients unwilling unable abide study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>STEMI</keyword>
	<keyword>AMI</keyword>
	<keyword>repair</keyword>
</DOC>